Interleukin-2-induced antinociception in morphine-insensitive rats
文献类型:期刊论文
作者 | Song, P; Liu, XY; Zhao, ZQ |
刊名 | ACTA PHARMACOLOGICA SINICA
![]() |
出版日期 | 2002 |
卷号 | 23期号:11页码:981-984 |
关键词 | antinociception interleukin-2 mu-opioid receptors |
通讯作者 | Zhao, ZQ (reprint author), Fudan Univ, Inst Neurobiol, Shanghai 200433, Peoples R China., |
英文摘要 | AIM: To investigate interleukin-2-induced antinociception in morphine-insensitive rats. METHODS: Paw withdrawal latencies (PWL) to noxious radiant heat were taken as the measurement of pain threshold. RESULTS: Intraplantar injection of human recombinant interleukin-2 (1.5 x 10(4) U) significantly increased PWL in normal rats. PWL was also markedly increased by IL-2 in 45-d-post-complete Freund's adjuvant (CFA)-treated rats, which have been proven morphine-insensitive. IL-2-induced antinociception in CFA-treated rats were significantly lower than that in normal rats. IL-2-induced antinociception was partially blocked by naloxone (1 mg/kg, ip) in normal rats but remained unchanged in CFA group. CONCLUSION: IL-2-induced antinociception is partially mediated by p-opioid receptors. Therapeutic applications of IL-2 may also be expanded to relieve morphine-insensitive pain. |
学科主题 | Chemistry; Pharmacology & Pharmacy |
类目[WOS] | Chemistry, Multidisciplinary ; Pharmacology & Pharmacy |
关键词[WOS] | EXPRESSION ; RECEPTORS ; ADJUVANT ; NEURONS ; IL-2 |
收录类别 | SCI |
语种 | 英语 |
WOS记录号 | WOS:000179049300004 |
版本 | 出版稿 |
源URL | [http://202.127.25.143/handle/331003/2535] ![]() |
专题 | 上海生化细胞研究所_上海生科院生化细胞研究所 |
推荐引用方式 GB/T 7714 | Song, P,Liu, XY,Zhao, ZQ. Interleukin-2-induced antinociception in morphine-insensitive rats[J]. ACTA PHARMACOLOGICA SINICA,2002,23(11):981-984. |
APA | Song, P,Liu, XY,&Zhao, ZQ.(2002).Interleukin-2-induced antinociception in morphine-insensitive rats.ACTA PHARMACOLOGICA SINICA,23(11),981-984. |
MLA | Song, P,et al."Interleukin-2-induced antinociception in morphine-insensitive rats".ACTA PHARMACOLOGICA SINICA 23.11(2002):981-984. |
入库方式: OAI收割
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。